Efficacy and safety of setmelanotide, an MC4R agonist, in individuals with severe obesity due to LEPR or POMC deficiency: single-arm, open-label, multicentre, phase 3 trials
Erstveröffentlichung
2020
Wissenschaftlicher Artikel
Published in
Lancet Diabetes & Endocrinology ; 8 (2020), 12. - S. 960-970. - ISSN 2213-8587. - eISSN 2213-8595